Barbara Paghera

Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy

Plasma β-amyloid in Alzheimer’s disease and vascular disease

The clinical use of structural MRI in Alzheimer disease

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blood protein predictors of brain amyloid for enrichment in clinical trials?

Does apolipoprotein E genotype modify the clinical expression of ALS?

Alzheimer's disease

Blood-Brain Barrier Breakdown in the Aging Human Hippocampus

3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

Alzheimer's disease

Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease

Inflammation as a central mechanism in Alzheimer's disease

Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting

Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1‐42 in Alzheimer's Disease Neuroimaging Initiative participants

Plasma tau in Alzheimer disease

Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF

Functional correlates of Apolipoprotein E genotype in Frontotemporal Lobar Degeneration

Preliminary Evidence of Validity of the Revised Criteria for Alzheimer Disease Diagnosis

A follow-up 18F-FDG brain PET study in a case of Hashimoto's encephalopathy causing drug-resistant status epilepticus treated with plasmapheresis

Supporting evidence for using biomarkers in the diagnosis of MCI due to AD

Markers of Alzheimer's disease in a population attending a memory clinic